Q3 EPS Estimate for Seres Therapeutics Reduced by Analyst

Seres Therapeutics, Inc. (NASDAQ:MCRB) – Equities researchers at HC Wainwright cut their Q3 2026 earnings per share estimates for shares of Seres Therapeutics in a report issued on Wednesday, August 5th. HC Wainwright analyst M. Keller now expects that the biotechnology company will earn ($1.34) per share for the quarter, down from their prior estimate of ($0.90). HC Wainwright has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for Seres Therapeutics’ current full-year earnings is ($5.84) per share. HC Wainwright also issued estimates for Seres Therapeutics’ Q4 2026 earnings at ($1.37) EPS, FY2026 earnings at ($4.36) EPS, FY2027 earnings at ($2.06) EPS and FY2028 earnings at ($2.17) EPS.

MCRB has been the subject of several other research reports. Wall Street Zen raised shares of Seres Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 6th. Zacks Research raised shares of Seres Therapeutics to a “hold” rating in a report on Tuesday, June 23rd. Finally, Weiss Ratings lowered shares of Seres Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday, May 18th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $17.00.

Seres Therapeutics Trading Down 3.8%

Shares of Seres Therapeutics stock opened at $4.82 on Friday. Seres Therapeutics has a 12-month low of $4.59 and a 12-month high of $29.98. The company has a market cap of $47.91 million, a price-to-earnings ratio of -1.98 and a beta of 0.20. The company’s 50-day moving average price is $6.23 and its 200-day moving average price is $8.48.

Seres Therapeutics (NASDAQ:MCRB) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported $0.47 earnings per share for the quarter, beating analysts’ consensus estimates of ($2.18) by $2.65. Seres Therapeutics had a negative return on equity of 112.11% and a negative net margin of 1,192.94%.The business had revenue of $0.74 million during the quarter, compared to analyst estimates of $0.18 million.

Institutional Investors Weigh In On Seres Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of MCRB. OMERS ADMINISTRATION Corp purchased a new position in Seres Therapeutics in the 4th quarter worth approximately $214,000. State Street Corp raised its position in shares of Seres Therapeutics by 14.0% during the 4th quarter. State Street Corp now owns 33,901 shares of the biotechnology company’s stock valued at $504,000 after buying an additional 4,170 shares in the last quarter. Vontobel Holding Ltd. raised its position in shares of Seres Therapeutics by 4.8% during the 4th quarter. Vontobel Holding Ltd. now owns 103,234 shares of the biotechnology company’s stock valued at $1,536,000 after buying an additional 4,723 shares in the last quarter. Goldman Sachs Group Inc. purchased a new stake in shares of Seres Therapeutics during the 4th quarter valued at $213,000. Finally, Geode Capital Management LLC lifted its holdings in shares of Seres Therapeutics by 1.4% during the 4th quarter. Geode Capital Management LLC now owns 86,142 shares of the biotechnology company’s stock worth $1,282,000 after acquiring an additional 1,160 shares during the last quarter. 59.34% of the stock is owned by hedge funds and other institutional investors.

Seres Therapeutics Company Profile

Seres Therapeutics is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.